Lanreotide
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Lanreotide: From Acromegaly/Neuroendocrine Tumours to Hypertrichosis
One-Sentence Summary
Lanreotide is a somatostatin analogue, established in clinical use for acromegaly and neuroendocrine tumours through suppression of the GH/IGF-1 axis. The TxGNN model predicts it may be effective for Hypertrichosis (disease), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-generated hypothesis only, and the underlying mechanistic rationale for this specific pairing is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acromegaly and neuroendocrine tumours (based on known clinical use of somatostatin analogues; not itemised in the source data) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this evidence pack (data gap). Based on known clinical information, Lanreotide is a somatostatin analogue whose efficacy in acromegaly and neuroendocrine tumours is established through inhibition of the growth hormone (GH)/IGF-1 axis and somatostatin receptor-mediated suppression of hormone secretion.
Hypertrichosis (excessive hair growth) is primarily driven by androgenic and follicular growth-regulatory pathways. The connection to the GH/IGF-1 axis is, at best, indirect and theoretical, and there is no clinical or preclinical evidence in this pack linking somatostatin receptor activity to hair follicle regulation. Given the absence of confirmed MOA data and the complete lack of supporting trials or literature, this candidate should be treated as a possible knowledge-graph artefact rather than a credible repurposing signal.
Notably, four further TxGNN candidates for this drug (malformation syndrome with dental/periodontal features, Dandy-Walker malformation syndrome, isolated genetic hair shaft abnormality, and Ambras-type congenital hypertrichosis) were also generated with similarly high scores (~99.96%) but represent congenital/structural developmental disorders with no known relationship to somatostatin signalling. This pattern — high confidence scores clustered around rare, mechanistically unrelated genetic conditions — is consistent with low-specificity prediction noise on sparsely connected disease ontology nodes, rather than a genuine pharmacological signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No marketing authorisation is currently held for this product in this evidence pack (market status: Not marketed; 0 licences on record).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: a blocking data gap exists — product label warnings and contraindications are not yet available in this evidence pack, which precludes any preliminary (S1) safety assessment for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: All five TxGNN-predicted indications for Lanreotide are Evidence Level L5 (model prediction only) with zero supporting clinical trials or literature, and the top-ranked candidate (hypertrichosis) lacks a credible mechanistic link to the drug’s known GH/IGF-1 suppressive action. A blocking data gap in safety labelling further prevents any preliminary safety review.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for Lanreotide
- SmPC/label warnings, contraindications and drug interaction data (currently a blocking gap)
- Independent mechanistic or preclinical evidence linking somatostatin receptor activity to hair follicle/androgen pathways before advancing beyond S0
- Re-evaluation once any clinical trial or published case evidence becomes available for this pairing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.